Cytoskeletal disarray increases arrhythmogenic vulnerability during sympathetic stimulation in a model of

Henrietta Cserne Szappanos1, Helena M Viola1, Danica W Ito2

  • 1School of Human Sciences, University of Western Australia, Crawley, WA, Australia.

Scientific Reports
|July 12, 2023
PubMed

Insights

Familial hypertrophic cardiomyopathy (FHC) mouse models show that altered ion channel function and beta-adrenergic signaling contribute to heart arrhythmias. These findings highlight potential therapeutic targets for FHC patients at risk of sudden cardiac events.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Familial hypertrophic cardiomyopathy (FHC) is linked to an increased risk of arrhythmias, particularly with strenuous exercise.
  • A mouse model with the MYH6 R403Q mutation mimics FHC, displaying cytoskeletal disarray and arrhythmia susceptibility.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying electrical instability in the R403Q FHC mouse model.
  • To explore the role of ion channel function and beta-adrenergic signaling in FHC-related arrhythmias.

Main Methods:

  • In vivo administration of isoproterenol to induce arrhythmias in mutant and wild-type mice.
  • Pharmacological interventions using atenolol (a beta-blocker) and PKI (a protein kinase A inhibitor).
  • Electrophysiological assessments of cardiac myocytes, including action potential recordings and analysis of connexin 43 expression. Super-resolution nanoscopy was used to assess CaV1.2 and beta-1 adrenergic receptor colocalization.

Main Results:

  • Mutant mice exhibited exacerbated tachyarrhythmias, poor recovery, and fatigue upon isoproterenol challenge.
  • Arrhythmias were significantly reduced by atenolol and PKI treatment.
  • Mutant myocytes displayed prolonged action potentials and triggered automaticity, linked to reduced repolarization reserve and connexin 43 levels.
  • While isoproterenol did not alter CaV1.2 current, it increased CaV1.2 phosphorylation and altered CaV1.2-beta-1 adrenergic receptor colocalization in mutant hearts.

Conclusions:

  • Altered ion channel expression, co-localization, and beta-adrenergic receptor signaling contribute to cardiac electrical instability in the R403Q FHC model.
  • These molecular changes, in conjunction with myocyte disarray, are key factors in the increased arrhythmia susceptibility observed in FHC.
  • The findings provide novel insights into FHC pathophysiology and suggest potential therapeutic strategies targeting ion channel and receptor signaling pathways.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
965
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
19
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11